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ABSTRACT 
The objectives of this study were to compare the clinical effects and glycemia induced by medetomidine and 
xylazine in healthy cats and to demonstrate the reversal of the effects by atipamezole. A prospective blinded 
randomized experimental trial was used with twenty-four healthy adult cats. The animals were allocated into 
4 groups of 6 animals each to receive by intramuscular route (IM): Group M (medetomidine - 50 μg/ kg); 
Group X (xylazine - 1.1 mg/kg); Group MA (medetomidine - 50 μg/kg and 60 minutes later atipamezole - 0.2 
mg/kg); Group XA (xylazine - 1.1 mg/kg and 60 minutes later atipamezole - 0.2 mg/kg). Rectal temperature, 
respiratory rate, heart rate, systolic arterial pressure, electrocardiogram, intraocular pressure, degree of 
sedation were measured at 0, 30, 60, 120 and 180 minutes, and the serum glucose concentration was 
measured at 0, 60, 120 and 180 minutes. The xylazine at a dose of 1.1 mg/kg and medetomidine at a dose 
of 50 μg/kg (both intramuscular) induced hypothermia, decreased heart rate, respiration and blood pressure 
and also 1st-degree A-V block in some cats, but it did not interfere significantly with intraocular pressure. The 
medetomidine induced a more pronounced hypothermia, sedation and hyperglycemia than xylazine in cats. 
The atipamezole was an excellent antagonist of the effects induced by medetomidine and xylazine in cats. 
Also, it did not interfere with the intraocular pressure values.  
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ESTUDO COMPARATIVO DOS EFEITOS DA MEDETOMIDINA E XILAZINA EM 
GATOS E REVERSÃO COM ATIPAMEZOLE  
 
 
 
RESUMO 
Os objetivos deste estudo foram comparar os efeitos clínicos e sobre a glicemia induzidos pela 
medetomidina e xilazina em gatos saudáveis e demonstrar a reversão destes efeitos pelo atipamezole. Um 
estudo prospectivo cego randomizado foi usado com vinte e quatro gatos adultos saudáveis. Os animais 
foram alocados em 4 grupos de 6 animais cada para receber por via intramuscular (IM): Grupo M 
(medetomidine - 50  μg/kg; Grupo X (xylazine – 1,1 mg/kg); Grupo o MA (medetomidine - 50 μg/kg e 60 
minutos após atipamezole - 0.2 mg/kg); Grupo XA (xylazine – 1,1 mg/kg e 60 minutos após atipamezole – 
0,2 mg/kg). Temperatura retal, freqüência respiratória, freqüência cardíaca, pressão arterial sistólica, 
eletrocardiograma, pressão intraocular, grau de sedação, foram medidos a 0, 30, 60, 120 e 180 minutos, e a 
concentração de glicose sérica medido a 0, 60, 120 e 180 minutos.  A xilazina a uma dose de 1,1 mg/kg e 
medetomidina a uma dose de 50  μg/kg (ambos por via intramuscular) induziu hipotermia, freqüência 
cardíaca, respiração e pressão arterial sanguínea diminuída e também bloqueio atrioventricular de 1
0 
grau 
em alguns gatos, mas não interferiu significativamente com pressão intraocular. A medetomidina induziu 
hipotermia, sedação e hiperglicemia mais pronunciada quando comparada a xilazina em gatos. O 
atipamezole foi um excelente antagonista dos efeitos induzidos por medetomidina e xilazina em gatos. 
Também, não interferiu com os valores de pressão intraocular. 
Palavras-chave: medetomidina; xilazina; atipamezole; gatos.  
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INTRODUCTION  
         The α2 agonists activate the central α2 
receptors, decreasing the release of dopamine 
and norepinephrine; inducing sedation, analgesia, 
mydriasis, bradycardia, hypothermia, transient 
hyperglycemia, polyuria, vomiting and intestinal 
impaction (MAZE; TRANQUILLI, 1991; RUFFOLO 
et al., 1994; SINCLAIR, 2003). They can also act 
on α1 receptors (SINCLAIR, 2003)
 
stimulating the 
sympathetic adrenergic α1 post-receptors located 
in the walls of arteries and veins causes initial 
hypertension followed by hypotension (RUFFOLO 
et al.,1994).    
In veterinary medicine, the first agonist to 
be used was xylazine, followed by romifidine, 
detomidine, medetomidine and more recently 
dexmedetomidine (SINCLAIR, 2003; MURRELL; 
HELLEBREKERS, 2005; GRANHOLM et al., 
2006).
 
 
Synthesized in 1962, xylazine is a potent α2 
agonist and a weak α1 adrenergic agonist. 
Medetomidine is a potent α2-selective adrenergic 
agonist and has a predominant action in the 
central nervous system. Medetomidine shows 
higher α2/α1 receptor selectivity than xylazine 
(VAINIO, 1989; VIRTANEN et al., 1989). 
Structurally, due to its imidazoline ring it may also 
have affinity to bind to the imidazoline receptors 
(VIRTANEN et al., 1989; MAZE; TRANQUILLI, 
1991; SINCLAIR, 2003). Atipamezole is 
considered a new generation α2-adrenergic 
antagonist because of its greater α2-adrenergic 
selectivity (VIRTANEN et al., 1989). This 
substance has no significant interaction with other 
types of receptors. In cats, it was proven to be a 
very potent and selective α2-adrenergic antagonist 
(VAHA-VAHE, 1990).  
The objective of this study was to compare 
the sedative, cardiac, respiratory and endocrine 
effects in cats after the use of α2-adrenergic 
agonists, medetomidine and xylazine and the 
reversal of those effects by atipamezole.  
MATERIALS AND METHODS 
The experiment was approved by the 
Ethical Committee of Unoeste (protocol n.016/07). 
In total, 24 mixed-breed adult healthy cats (14 
males and 10 females), obtained from the 
UNOESTE cat facility, and with a mean age of 3 
years and a mean weight of 3.3±5.1 kg were 
used. After the experiment all of the cats were put 
in the pet program for adoption of the University. 
The cats were deemed healthy by full blood work 
and physical exam. One day before running the 
experiment, the cats were socially isolated and 
held in individual stainless steel cages under a 
12:12 artificial light-dark cycle. The room 
temperature was about 25°C and they were fed 
ad libitum with dry commercial diet. Two 
observers (always the same along the 
experiment) manipulated the cats in this 
acclimatization period (24 hours before the 
experiment) to get familiar with them. The 
information was blinded on whether the 
experimental group the observer was evaluating.  
The cats were randomly allocated into 4 
groups of 6 animals each as follows: Group M 
(medetomidine - Domitor
®
, Pfizer) received 50 
μg/kg intramuscularly (im) at a 1 mg/mL 
concentration and 0.1 ml/kg in physiologic saline 
solution 0.9% (Physiologic saline solution 0.9%
®
, 
Fresenius Kabi) 60 minutes later; Group X 
(xylazine - Ronpum
®
, Bayer) received 1.1 mg/kg 
im at a 20 mg/mL concentration and 0.1 ml/kg im 
physiologic saline solution 0.9% 60 minutes later; 
Group MA (medetomidine/atipamezole - 
Antisedan
®
, Pfizer) received medetomidine at 
same dose and concentration of Group M and 
atipamezole 0.2 mg/kg im at a 5 mg/ml 
concentration 60 minutes later; Group XA 
(xylazine/atipamezole) received xylazine at same 
dose and concentration of Group X and 
atipamezole 0.2 mg/kg im at a 5 mg/ml 
concentration 60 minutes later.  
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The values of temperature (T), respiratory 
rate (RR), heart rate (HR), systolic arterial 
pressure (SAP), electrocardiogram (ECG), 
intraocular pressure (IOP) and degree of sedation 
(DS) were measured at time zero (T0) before the 
administration of the α2-adrenergic agonists; and 
30, 60, 120 and 180 minutes after the 
administration of the α2-adrenergic agonists. DS 
was considered: (0) absent, (1) discreet - low 
ataxia and protective reflexes present, (2) 
moderate - reduced protective reflexes and ataxia, 
and (3) high - lateral decubitus and protective 
reflexes reduced or absent. Mean interval for 
sedation return (MISR) was considered to be the 
time (min) necessary for the animal to recover 
protective pupillary, palpebral, and interdigital 
reflexes (ANDRADE et al, 2006). The animal had 
to stand up without ataxia after the atipamezole 
administration. The data was always assessed by 
two observers. Adverse effects as vomiting, 
diarrhea, sialorrhea, diuresis, vocalization, 
tremors, and 3rd eyelid prolapse were evaluated 
at the end of the treatments. 
Systolic arterial pressure was measured by 
an indirect or non-invasive method with Doppler 
Ultrasonic equipment (Parks Medical-841-A). The 
transducer was placed on the palmer surface of 
the left forelimb over the common digital branch of 
the radial artery to detect blood flow, and a blood 
pressure monitoring cuff with a width 37% the limb 
circumference was placed half way between the 
elbow and the carpus (GRANDY et al., 1992; 
BINNS et al., 1995; SPARKES et al., 1999). An 
electrocardiogram of the cats in right lateral 
recumbency was recorded (Cardiotest EK51). A 
mean value of 5 consecutive heart beats was 
recorded on lead II (paper speed of 50 mm/s, 1 
cm = 1 mv) for each parameter. The cardiac 
rhythm was evaluated by occurrence of a) sinusal; 
b) sinusal arrhythmia; c) sinusal bradycardia; d) 
1st degree A-V block; or e) sinus arrest (TILLEY; 
GOODWIN, 2001). For IOP measurements, 
applanation tonometry using a Perkins tonometer 
(Clement Clarke) was completed. There was 
instillation of one drop of anesthetic eye drop and 
one drop of fluorescein eye drop before the exam 
(ANDRADE et al., 2009). The serum glucose was 
measured at 0, 60, 120 and 180 minutes after 
administration of the 2 agonists. The blood 
samples were collected by jugular puncture. 
 The variables were measured between the 
different groups and compared using an analysis 
of variance (ANOVA) with contrasts using the 
Tukey method. An identical procedure was used 
to compare the different times within each group. 
Variables that did not show a normal distribution 
by the Kolmogorov and Smirnov test were 
submitted to the Kruskal-Wallis test for 
comparison between the groups and the 
Friedman test for comparison between the 
moments. In both cases, contrasts of Dunn were 
used. A significance level of P < 0.05 was 
adopted. 
 
RESULTS  
         Both medetomidine and xylazine decreased 
temperature significantly from 30 to 180 min 
compared to the baseline (T0). Medetomidine 
induced hypothermia more significantly than 
xylazine at 120 and 180 min (P < 0.05). This effect 
was reduced by atipamezole, with temperatures 
returning close to basal values in 180 min (Table 
1). 
The 2 agonist’s administration reduced the 
respiratory rate from 160 min to 180 min 
compared to the T0. However, this decreased RR 
was abolished in groups receiving atipamezole 
(Table 1).  
Heart rate was decreased by medetomidine 
from 30 min to 120 min and by xylazine from 30 
min to 180 min. Atipamezole reestablished HR 
after 120 min (Table 1). Medetomidine and 
xylazine decreased SAP from 120 to 180 min 
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compared to the T0. Atipamezole was efficient in 
reversing this situation (Table 1). 
There was no statistical difference with the 
use of medetomidine, xylazine, or atipamezole in 
the IOP measured values (Table 1). Concerning 
the variable degree of sedation (DS), 
medetomidine and xylazine induced high DS from 
30 to 60 min, moderate DS for 120 min and 
discreet DS at 180 min. After atipamezole 
administration, the DS returned to absent (Table 
2). 
Cardiac rhythm was affected by 
medetomidine at 30 min and by xylazine at 60 min 
(Table 2). After atipamezole administration, the 
cardiac rhythm was normal for cats (sinusal). 
Some cats presented with 1st-degree A-V block 
during the experiment (one cat in group M, two 
cats in group MA, one cat of Group X and one cat 
in group XA). 
Regarding the glucose variables, the 2 
agonists increased glucose levels in all groups 
(Table 3), but this effect was more significant with 
medetomidine from 60 to 180 min. Medetomidine 
induced hyperglycemia until the end (249.7±170.4 
mg/dL), while xylazine only induced 
hyperglycemia for 120 min (141.0±52.3 mg/dL) 
(Table 3). Cats receiving atipamezole 
reestablished these earlier levels at 120 min. 
The mean interval for sedation return 
(MISR) was significantly increased with 
medetomidine (123.5±410.1 min) compared to 
xylazine (87.5±35.9 min) (P < 0.05). The MISR 
was drastically reduced by atipamezole in both 
groups, and there was no significantly difference 
(P > 0.05) between group MA (2.0±1.0 min) and 
group XA (2.5±1.2 min).  
The other clinical signs investigated as 
vomit, sialorrhea, tremor and 3rd eyelid prolapse 
are shown in Table 4. 
 
 
 
DISCUSSION 
Cats are very susceptible to hypothermia 
with the use of α2 adrenergic agonists (MICHELL, 
1994). Alpha-adrenergic agonists induce 
hypothermia because they affect the 
thermoregulation center in the hypothalamus 
(MACDONALD; SCHEININ, 1995).  
The decrease in respiratory rate that may 
occur is due to the α2-adrenergic inhibition of the 
state neurons located in the ventral portion of the 
brain (RUFFOLO et al., 1994; SINCLAIR, 2003). 
At high doses of α2-adrenergic agonists can 
reduce the sensitivity of the breathing center to 
increased PCO2, accentuating breathing 
depression (MICHELL, 1994). In the experiment 
the respiratory rate in relation to the basal values, 
maintained inside of the physiologic limits for the 
species, doesn't tend clinical relevance, 
independent of the administration of the 
atipamezole.  
Heart rate was depressed in all groups for 
30 min after administration. It was also shown that 
the mean heart rate of animals treated with 
atipamezole showed a relative increase. An 
increased heart rate induced by α2 antagonist 
adrenergics is consistent with other author´s 
descriptions in cats (NILSFORS; KVART, 1996). 
Some authors reported that medetomidine causes 
similar but more severe cardiopulmonary effects 
than xylazine (NILSFORS; KVART, 1996; 
PYPENDOP; VERSTEGEN, 1998; SINCLAIR, 
2003), but in the present experiment, the effects 
observed in RR, HR and SAP induced by 
medetomidine and xylazine are very similar. The 
decrease in systolic blood pressure is due to the 
depressant effect of xylazine on the heart rate and 
contractility, resulting in a decreased cardiac 
output (GREENE; THURMON, 1988; 
PADDLEFORD; HARVEY, 1999).  
Medetomidine has been shown to induce a 
higher degree of sedation than xylazine. This 
difference is probably due to its increased affinity 
 Colloquium Agrariae, v. 7, n.1, Jan-Jun. 2011, p. 52-60. DOI: 10.5747/ca.2011.v07.n01.a066 
56 
and selection of the central pre-synaptic α2-
receptors (SINCLAIR, 2003; CULLEN, 1996). The 
α2 adrenergic agonists depress the central 
nervous system, causing a reduction in the 
release of noradrenalin centrally and peripherally. 
Furthermore, they promote sedation and muscle 
relaxation by inhibition of interneural medullary 
transmission (MAZE; TRANQUILLI, 1991). There 
was rapid reversal of sedation in the groups 
treated with atipamezole. This was due to its 
excellent antagonist selectivity for α2 receptors 
(VAHA-VAHE, 1990). 
Arrhythmias caused by α2-adrenergic are 
probably due to reduced CNS sympathetic tonus 
and increased parasympathetic activity 
(PADDLEFORD; HARVEY, 1999; PYPENDOP; 
VERSTEGEN, 1998). In this experiment, only 
sinusal arrhythmia and 1st A-V block were 
observed. It is important to emphasize, that in this 
study only 5 consecutives HR and ECG readings 
were made and no others cardiovascular 
parameters were taken as longer ECG strips or 
holter monitors, so some arrhythmias might be 
missed during all the experimental time.  
There was no effect of xylazine at a dose of 
1.1 mg/kg IM and medetomidine at a dose of 50 
μg/kg IM on the measured values of the IOP. 
These findings are consistent with the use of 
medetomidine in dogs (VERBRUGGEN et al., 
2000). In cats, the topical use of medetomidine 
and xylazine decreases IOP (BURKE; POTTER, 
1986a; BURKE; POTTER, 1986b; JIN et al., 
1991). 
 
The cats showed significant hyperglycemia 
after medetomidine administration from 60 min 
until 180 min. This finding is in agreement with 
others reports (BURTON et al., 1997; KANDA; 
HIKASA, 2008) that hyperglycemia induced by 
medetomidine is greater than xylazine in cats and 
that cats are more susceptible to hyperglycemia 
induced by α2 adrenergic agonists than dogs. 
Induction of hyperglycemia occurs through 
inhibition of the secretion of insulin, which is 
mediated by α2-adrenergic receptors; specifically, 
the subtype α2D is located in the pancreatic islets 
(ANSAH et al., 1998; ABU-BASHA et al., 1999; 
KANDA; HIKASA, 2008). There was a reversal of 
hyperglycemia in the groups treated with 
atipamezole. Atipamezole is capable of reversing 
hyperglycemia induced by α2 adrenergic agonists.  
The MISR showed significant differences 
between the experimental groups. Animals treated 
with medetomidine showed a greater duration of 
sedation compared to those treated with xylazine. 
Medetomidine and xylazine induced sedation, 
analgesia and muscle relaxation dose-dependent 
and very significant in cats (CULLEN, 1996). 
Although the difference was not significant, there 
was a quicker reversal after administration of 
atipamezole in the MA group than in the XA 
group. It is important to report that all the animals 
recovered very well from medetomidine and 
xylazine sedation, in spite of some side effects 
they have been observed in the experimental 
groups and they be described in the Table 4.  
Xylazine at a dose of 1.1 mg/kg and 
medetomidine at a dose of 50 μg/kg (both 
intramuscular) did not interfere significantly with 
intraocular pressure. They induced hypothermia, 
sinusal arrhythmia, 1st-degree A-V block, 
decreased heart rate, respiration and blood 
arterial pressure. Medetomidine induced 
hypothermia, sedation and more prolonged 
hyperglycemia than xylazine in cats. Atipamezole 
was an excellent antagonist of the effects induced 
by medetomidine and xylazine in cats. Also, it did 
not interfere with the measured IOP values.  
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Table 1. Means and standard deviations (Means ± SD) of the variables: temperature (T), heart rate (HR), 
respiratory rate (RR), systolic blood pressure (SBP) and intraocular pressure (IOP), according to the different 
intervals of time . 
Variable Group Time (minutes) 
T0 T30 T60 T120 T180 
 
 
T 
 
M 37.8±0.4 Aa 37.9±0.4 Aa 36.4±0.5 Ab 34.9±0.7 Cb 35.5±0.8 Cb 
MA 37.9±0.6 Aa 36.6±0.7 Aa 36.1±0.7 Ab 36.0±1.0 Bb 36.8±1.0 Ba 
X 37.7±0.4 Aa 37.5±0.8 Aa 36.8±0.5 Ab 36.2±0.5 Bb 36.1±1.0 Bb 
XA 38.1±0.6 Aa 37.6±0.8 Aa 36.7±0.7 Ab 36.5±1.1 Bb 37.5±0.9 Ba 
 
 
RR 
 
M 50.0±5.5 Aa 50±12.3 Aa 38.2±6.8 Ab 30.7±5.5 Ab 37.3±7.9 Ab 
MA 43.0±13.2 Aa 30.5±6.3 Ba 27.7±8.2 Bb 45.3±18.5 Aa 40.7±4.7 Aa 
X 32.7±9.6 Ba 41.3±10.0 Ba 26.3±2.7 Bb 38.7±6.4 Aa 31.0±8.2 Aa 
XA 38.7±4.7 Ba 32.7±6.9 Ba 30.0±4.9 Aa 37.3±17.5 Aa 38.7±7.8 Aa 
 
 
HR 
M 132.7±21.2Aa 112.7±23.0 Ab 115.3±20.4 Ab 113.0±14.6 Ab 145.3±22.9 Aa 
MA 132.3±27.7Aa 90.7±16.1 Bb 90.0±12.6 Bb 151.7±29.6 Bc 169.7±27.8 Bc 
X 144.0±20.4 Aa 124.0±15.0 Ab 102.0±9.7 Bb 104.7±7.8 Ab 111.0±15.0 Ab 
XA 160.7±8.2 Aa 106.7±21.7 Bb 108.3±20.0 Bb 156.7±38.8 Ba 164.0±40.2 Ba 
 
 
SAP 
 
M 162.5±23.2 Aa 173.3±36.7 Aa 163.8±30.9 Aa 149.2±23.3 Bc 145.8±19.1 Bc 
MA 172.8±24.0 Aa 170.0±19.7 Aa 160.8±26.0 Aa 187.5±30.6 Aa 170.0±14.1 Aa 
X 169.2±18.0 Aa 158.3±22.1 Aa 158.3±20.4 Aa 146.7±19.7 Bc 155.0±16.4 Bc 
XA 160.0±0.0 Aa 133.3±46.0 Bb 153.3±25.0 Aa 173.3±25.0 Aa 175.0±12.2 Aa 
 
 
IOP 
 
M 14.3±0.2 Aa 13.1±0.1 Aa 13.1±0.2 Aa 14.1±0.1 Aa 15.4±0.2 Aa 
MA 14.5±0.1 Aa 13.1±0.1 Aa 13.1±0.1 Aa 14.2±0.1 Aa 14.7±0.1 Aa 
X 15.4±0.1 Aa 14.3±0.1 Aa 14.3±0.1 Aa 13.1±0.1 Aa 14.3±0.1 Aa 
XA 15.5±0.1 Aa 15.4±0.1 Aa 15.4±0.1 Aa 15.8±0.1 Aa 15.9±0.1 Aa 
Reference values: 38.1-39.2°C (T); 20-50 mov/min (RR); 120-240 bpm (HR); 120-170 mmHg (SAP) (BISTNER et al., 2000); 13-21 
mmHg (IOP) (ANDRADE et al., 2009). 
Upper-case letters compare groups at a same time (Kruskal-Wallis test). 
Lower-case letters compare times within each group (Friedman test). 
Same letters indicate no significant difference (P > 0.05). 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups 
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Table 2. Medians (quartiles P25;P75) of the variables degree of sedation and cardiac rhythm according to 
the different intervals of time . 
Variable Group Time (minutes) 
T0 T30 T60 T120 T180 
 
 
Degree of 
Sedation 
 
M 0 (0;0) Aa 
 
3 (2;3) Bb 3 (2;3) Bb 2 (1;2) Cc 1 (1;2) Dd 
MA 0 (0;0) Aa 
 
3 (2;3) Bb 3 (2;3) Bb 0 (0;0) Aa 0 (0;0) Aa 
X 0 (0;0) Aa 
 
3 (2;3) Bb 3 (2;3) Bb 2 (1;2) Cc 1 (1;1) Dd 
XA 0 (0;0) Aa 
 
3 (2;3) Bb 3 (2;3) Bb 0 (0;0) Aa 0 (0;0) Aa 
 
 
Cardiac rhythm 
M 1 (1;1) Aa 
 
2 (2;4) Bb 2 (2;2) Bb 1 (1;1) Aa 1 (1;2) Aa 
MA 1 (1;1) Aa 
 
2 (1;2) Bb 2 (1;4) Bb 1 (1;1) Aa 1 (1;2) Aa 
X 1 (1;1) Aa 
 
1 (1;1) Aa 2 (1;4) Bb 1 (1;2) Aa 1 (1;1) Aa 
XA 1 (1;1) Aa 
 
1 (1;2) Aa 2 (1;4) Bb 1 (1;1) Aa 1 (1;1) Aa 
Degree of Sedation was considered: (0) absent, (1) discreet - low ataxia and protective reflexes present, (2) moderate - less protective 
reflexes and ataxia, and (3) high - lateral decubitus and protective reflexes reduced or absent 
Cardiac rhythms: sinusal (1). sinusal arrhythmia (2). sinusal bradycardia (3). 1st-degree A-V block (4).  sinus arrest (5). Normal rhythm: 
sinusal (TILLEY and GOODWIN, 2001). 
Upper-case letters compare groups at a same time (Kruskal-Wallis test). 
Lower-case letters compare times within each group (Friedman test). 
Same letters indicate no significant difference (P > 0.05). 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups. 
 
Table 3. Means and standard deviations (Means ± SD) of the variable glucose, according to the different 
intervals of time . 
Variable Group Time (minutes) 
T0 T60 T120 T180 
 
Glucose 
M 75.8±21.1 Aa 168.3±170.7Bb 223.0±108.8 Bc 249.7±170.4 Bc 
MA 73.1±9.9 Aa 137.7±57.6 Cb 91.0±30.7 Dc 66.7±8.5 Aa 
X 72.9±13.0 Aa 132.8±37.1 Cb 141.0±52.3 Cb 110.1±46.3 Cb 
XA 74.3±10.1 Aa 141.0±35.3 Cb 79.2±25.8 Aa 63.2±9.7 Aa 
Reference values: glucose (73-134 mg/dL) (KANEKO, 1997) . 
Upper-case letters compare groups at each time (Kruskal-Wallis test). 
Lower-case letters compare times within each group (Friedman test). 
Same letters indicate no significant difference (P > 0.05). 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups. 
 
Table 4. Number (and percentage) of cats showing clinical signs after the administration of protocol 
treatment of each experimental group. 
Groups Vomit Sialorrhea Tremors 3rd Eyelid Prolapse 
M 3 
(50.0%) 
2 
(33.3%) 
0 
(0%) 
3 
(50.0%) 
MA 1 
(16.7%) 
2 
(%) 
1 
(%) 
0 
(0%) 
X 4 
(66.7%) 
3 
(50.0%) 
1 
(16.7%) 
1 
(16.7%) 
XA 
 
5 
(83.3%) 
3 
(50.0%) 
1 
(16.7%) 
0 
(0%) 
Data from 6 cats each group. 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups 
 
 
